Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.719895279.793511926 ◽

2015 ◽

Cited By ~ 1

Author(s):

Andrew Gennery

Keyword(s):

Stem Cell ◽

Haemopoietic Stem Cell Transplantation

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Haemopoietic Stem Cell ◽

Open Label Phase ◽

Randomised Controlled ◽

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(11)61938-7 ◽

2012 ◽

Vol 379 (9823) ◽

pp. 1301-1309 ◽

Cited By ~ 185

Author(s):

Selim Corbacioglu ◽

Simone Cesaro ◽

Maura Faraci ◽

Dominique Valteau-Couanet ◽

Bernd Gruhn ◽

...

Keyword(s):

Stem Cell ◽

Haemopoietic Stem Cell Transplantation

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Haemopoietic Stem Cell ◽

Open Label Phase ◽

Randomised Controlled ◽

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

The Lancet ◽

10.1016/s0140-6736(19)31240-1 ◽

2019 ◽

Vol 394 (10192) ◽

pp. 29-38 ◽

Cited By ~ 191

Author(s):

Philippe Moreau ◽

Michel Attal ◽

Cyrille Hulin ◽

Bertrand Arnulf ◽

Karim Belhadj ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Autologous Stem Cell Transplantation ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Cassiopeia A ◽

Before And After ◽

Open Label Phase

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

The Lancet Haematology ◽

10.1016/s2352-3026(20)30099-5 ◽

2020 ◽

Vol 7 (6) ◽

pp. e456-e468 ◽

Cited By ~ 30

Author(s):

Michele Cavo ◽

Francesca Gay ◽

Meral Beksac ◽

Lucia Pantani ◽

Maria Teresa Petrucci ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Haematopoietic Stem Cell Transplantation ◽

Haematopoietic Stem Cell ◽

Consolidation Therapy ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

The Lancet Haematology ◽

10.1016/s2352-3026(18)30149-2 ◽

2018 ◽

Vol 5 (10) ◽

pp. e479-e492 ◽

Cited By ~ 12

Author(s):

Niels WCJ van de Donk ◽

Bronno van der Holt ◽

Monique C Minnema ◽

Edo Vellenga ◽

Sandra Croockewit ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Controlled Trial ◽

Long Term Results ◽

Phase 3 ◽

Before And After ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Global Health ◽

10.1016/s2214-109x(19)30427-9 ◽

2019 ◽

Vol 7 (12) ◽

pp. e1706-e1716 ◽

Cited By ~ 6

Author(s):

Sutapa B Neogi ◽

Niveditha Devasenapathy ◽

Ranjana Singh ◽

Himanshu Bhushan ◽

Duru Shah ◽

...

Keyword(s):

Pregnant Women ◽

Controlled Trial ◽

Intravenous Iron ◽

Severe Anaemia ◽

Iron Sucrose ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950273.793455532 ◽

2012 ◽

Author(s):

Alexander Eggermont

Keyword(s):

Metastatic Melanoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study

The Lancet Haematology ◽

10.1016/s2352-3026(14)00022-2 ◽

2014 ◽

Vol 1 (3) ◽

pp. e112-e119 ◽

Cited By ~ 6

Author(s):

Anna Kalff ◽

Nola Kennedy ◽

Angela Smiley ◽

H Miles Prince ◽

Andrew W Roberts ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Final Analysis ◽

Consolidation Therapy ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3